Regen Lab CEO and Founder Mr. Antoine Turzi discusses the company’s research evolution and pioneering advances in biotherapeutics in an interview with SmartTRAK.
Regen Lab is a leader in autologous regenerative medicine and cell therapy devices. The company’s extensive patented platform combines autologous platelet-rich plasma (PRP) with hyaluronic acid (HA). Regen Lab’s innovation and technological advancements extend across various fields, including musculoskeletal disorders, aesthetics/cosmetic surgery, wound care and intimate health.
In a recent interview withSmartTRAK, Antoine Turzi, CEO and Founder of Regen Lab, discusses the company’s research evolution and pioneering advances in biotherapeutics, with a special focus on its Cellular Matrix PRP-HA technology.
To find out more, click on the following video (43:20 min). A link to download a complete transcript of the interview is also provided below.
Interview Transcript
Hello, this is Freddy Buntoum with SmartTRAK and I’m here today with Mr. Antoine Turzi, the CEO and founder of Regen Lab. Good afternoon, Antoine, and first off, can you tell us a little bit about your professional background and how you would describe Regen Lab to someone who had no idea what your company is all about?
Antoine Turzi: Okay, Freddy, first of all, thank you for having me. Happy to see you again. And yes, happy to speak about my recent career in this regenerative medicine field. Regen, take his name from regenerative medicine. And 25 years ago when I started, I must say that it was a new growing field, very little experience. And one of the first cellular therapy that was understood was the PRP.
And it is true that, when we started working in this field, we were looking for technology, look at what’s existing on the market. There was some technology existing in the United States, but based on plastic container without separator means of the blood components and the result somewhat were quite poor. It was similar to a buffy coat technique described by Dr. Cohn in the year 60 when they were the first understanding and publication of how to make the blood fraction and red separation.
And of course, those techniques were not satisfactory because the platelet count was not high and the clinical outcome was medium. So I took the initiative to speak with Becton Dickinson. They were experts in the tube and blood fractioning and we designed together the first …
Click the button below to download a complete transcript of Regen Lab CEO Antoine Turzi discussing the company’s research evolution and pioneering advances in biotherapeutics in an exclusive interview with Freddy Buntoum, SmartTRAK Senior Analyst, Orthobiologics and Regenerative Medicine. Read More